DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Soft Tissue Sarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
“The total Soft Tissue Sarcoma market size, excluding Gastrointestinal stromal tumors (GIST) in seven major markets was USD 246.7 million in 2017.”
Report Highlights:
- In the coming years, Soft Tissue Sarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Soft Tissue Sarcoma market size to enable the drug manufacturers to penetrate more into the market
- Major players like Blueprint Medicines Corporation, Gradalis, Karyopharm Therapeutics and many others are involved in developing therapies for Soft Tissue Sarcoma. Launch of emerging therapies will significantly impact the Soft Tissue Sarcoma market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Soft Tissue Sarcoma
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
REQUEST FOR SAMPLE PAGES: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Table of contents
1. Key Insights
2. Executive Summary of Soft-Tissue Sarcoma
3. Soft-Tissue Sarcomas Market Overview at a Glance
4. Soft-Tissue Sarcoma Disease Background and Overview
5. Soft-Tissue Sarcoma Epidemiology and Patient Population
6. Case Reports
7. Country Wise Soft-Tissue Sarcoma Epidemiology
7.1. United States Epidemiology
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan Epidemiology
8. Soft-Tissue Sarcoma Treatment and Management
9. Unmet Needs
10. Soft-Tissue Sarcoma Marketed Drugs
10.1. Halaven (Eribulin Mesylate): Eisai
10.2. Gleevec (Imatinib Mesylate): Novartis
10.3. Yondelis (Trabectedin): Pharma Mar
10.4. Lartruvo (Olaratumab): Eli Lilly
10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
10.6. Stivarga (Regorafenib): Bayer
10.7. Sutent (Sunitinib malate): Pfizer
10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
10.9. Vincristine Sulfate: Hospira
10.10. Rozlytrek (Entrectinib): Roche (Genentech)
11. Soft-Tissue Sarcoma Emerging Drugs
11.1. Key Cross Competition- Phase III Emerging Molecules
11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation
11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis
11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
11.5. Selinexor: Karyopharm Therapeutics
11.6. Aldoxorubicin (INNO-206): CytRx
11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
11.8. Fibromun (In combination with Doxorubicin): Philogen
11.9. Hensify (NBTXR3): Nanobiotix
11.10. Crenolanib: Arog Pharmaceuticals
11.11. TAS-116: Taiho Pharmaceutical
11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune
11.13. ADP-A2M4: Adaptimmune
12. Soft Tissue Sarcoma 7 Major Market Analysis
13. Market Outlook: The United States
13.1. United States Market Size
14. Market Outlook: Europe
14.1. Germany
14.2. France
14.3. Italy
14.4. Spain
14.5. United Kingdom
15. Soft-Tissue Sarcoma Market Outlook: Japan
16. Access and Reimbursement Overview of Soft-Tissue Sarcoma
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/